


PHARMACEUTICAL 2017



PIERIS PHARMACEUTICALS INC. Rank 191 of 313





PHARMACEUTICAL 2017



PIERIS PHARMACEUTICALS INC. Rank 191 of 313

The relative strengths and weaknesses of PIERIS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PIERIS PHARMACEUTICALS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 65% points. The greatest weakness of PIERIS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is -291%, being 126% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	32,673
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,380
Liabilities, Non-Current	47
Other Assets	126
Other Compr. Net Income	-229
Other Expenses	162
Other Liabilities	1,409
Other Net Income	122
Property and Equipment	2,264
Research and Development	19,699
Revenues	5,831
Selling, General and Administrative Expense	8,891

Output Variable	Value in 1000 USD
Assets	35,063
Liabilities	9,836
Expenses	28,752
Stockholders Equity	25,227
Net Income	-22,799
Comprehensive Net Income	-22,914
Economic Capital Ratio	-291%